Skip to main content

Aura Biosciences, Inc.

AURA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501796

No open-market purchases or sales by Aura Biosciences, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $677.2M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aura Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aura Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aura Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Person JulieChief People Officer107,611Sep 1, 20261
Kratz EricaChief Reg. & Quality Officer100,885Sep 1, 20261
Hopkins Janet JillChief Medical Officer380,190Sep 1, 20264
Elazzouzi AmySVP, Finance & PAO143,600Sep 1, 20265
Abu-Absi SusanChief Operating Officer134,513Sep 1, 20261
Bender JeremyDirector30,000Jul 8, 20261
Kilroy ConorSee Remarks232,693Jul 1, 20264
Gibney Anthony SSee Remarks265,354Jun 16, 20262
Srivastava SapnaDirector38,500Jun 15, 20261
Mattessich Antony C.Director38,500Jun 15, 20261
Johnson David MichaelDirector194,167Jun 15, 20261
Bitetti Teresa MarieDirector36,000Jun 15, 20261
Holles Natalie C.See Remarks1,153,962May 19, 20261
Matrix Capital Management Company, LP10% Owner0IndirectMay 11, 20261
Goel David E.10% Owner0IndirectMay 11, 20261
Plavsic MarkChief Technology Officer243,736Mar 3, 20263
de los Pinos ElisabetSee Remarks575,815Mar 3, 20264
Feder Julie BChief Financial Officer134,276Oct 21, 20240
Parekh Rajesh BDirector–Jun 9, 20230
De Rosch MarkChief Operating Officer58,635Jan 23, 20230
Rich CadmusSee Remarks58,703Jan 23, 20230
Medicxi Growth I LP10% Owner70,540IndirectNov 4, 20210
Medicxi Growth Co-Invest I LP10% Owner70,540IndirectNov 4, 20210
Medicxi Ventures Management (Jersey) Ltd10% Owner70,540IndirectNov 4, 20210
Medicxi Growth I GP Ltd10% Owner70,540IndirectNov 4, 20210
Primiano Christopher BrettChief Business Officer8,750Oct 29, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 17, 2026 (view filing)Feb 17Same dayHopkins Janet JillChief Medical OfficerSSale−20.4K$5.06−$103.2K−8.1%232.3K after
Feb 17, 2026 (view filing)Feb 17Same dayPlavsic MarkChief Technology OfficerSSale−15.9K$5.05−$80.2K−8.1%181.4K after
Feb 17, 2026 (view filing)Feb 17Same dayKilroy ConorSee RemarksSSale−12.1K$5.05−$61.0K−6.7%167.2K after
Apr 16, 2026 (view filing)Apr 16Same dayKilroy ConorSee RemarksSSale−11.7K$7.02−$82.4K−5.1%217.8K after
May 11, 2026 (view filing)4:16 PM ETMay 74 daysMatrix Capital Management Company, LP and 1 other10% OwnerSSaleCommon Stock, par value $0.00001 per share (Common Stock)−6.92M$5.64−$39.0M−100.0%0 after
Jun 16, 2026 (view filing)Jun 16Same dayGibney Anthony SSee RemarksSSale−12.8K$6.42−$82.3K−4.6%265.4K after